Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treatment-free remission in CML

Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.

Key clinical point: Second-line nilotinib led to treatment-free remission in CML patients who achieved sustained molecular response.

Major finding: In total, 58% of patients who switched to nilotinib experienced treatment-free remission at 48 weeks.

Study details: A single-group, open-label phase 2 study.

Disclosures: Novartis Pharmaceuticals funded the study. The researchers reported financial ties to Novartis and other pharmaceutical companies.

Source: Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.

Read the article.

Citation:

Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.